Key result
Cardiac biomarkers, particularly cardiac troponins, are essential for the rapid diagnosis and effective management of acute myocardial infarction.
Cardiac biomarkers, particularly troponins, remain the gold standard for early diagnosis of acute myocardial infarction, while emerging serum and salivary markers offer potential for more rapid and non-invasive assessment.
Answers are grounded in this paper and cite their sources.
Troponins remain central to AMI diagnosis; literature review leaves open whether emerging markers improve speed or outcomes in practice.
Acute myocardial infarction (AMI) is a major cause of morbidity and mortality worldwide. The highest risk of fatality occurs within the initial hours of onset of AMI. Thus, early diagnosis of cardiac ischemia is critical for the effective management of patients with AMI. Improper diagnosis of patients with chest pain often leads to inappropriate admission of patients without AMI and vice versa. In addition to clinical history, physical examination, accurate electrocardiogram findings and assessment of cardiac biomarkers have an important role in the early diagnosis of acute ischemia. The present review discusses in detail the various cardiac biomarkers released during the event of an AMI.
No takes yet. Share an insight, caveat, or question.
Mythili Sabesan (2015) conducted a review in Acute myocardial infarction. Cardiac biomarkers was evaluated. Cardiac biomarkers, particularly cardiac troponins, are essential for the rapid diagnosis and effective management of acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: